'BioInvestor4', the company just hired one of the top CRO's. Is this not a good achievement?

I personally see progress being made here. In the Bio world, everything takes quite some time to achieve.

This company has to get the IND submitted perfectly, otherwise all this time, theirs, our $$$ has been wasted.

As an long-term investor here, I personally like the silence by the company. It tells me that things are happening behind the scenes.

Extreme patience is required here.

Any one see this on Austrianova's Facebook this am?

Austrianova
4 hrs ·
Nice to see PharmaCyte’s latest press release about the completion of the safety assessment report on placement of encapsulated cells in which Austrianova CTO Walter Gunzburg and our long term colleague Prof. Udo Losert played a role - a good culmination to the earlier reported meeting with Prof. Losert

'penny2017investor', No money has been made off of investors here for quite some time now.

Not when the share price has been sitting @ $0.0001 - $0.0002 for years. This has not been diluted for quite some time now. All my own HOMO though.

It could happen at any time here.

Wow, a 20 million buy at the ask. At this rate, the $0.0002's will be gone soon.

The company is currently working on an opportunity to further expand its investment in American Health Network through the addition of health and wellness partners.

https://www.ahni.com/

FOR IMMEDIATE RELEASE
August 31, 2018
WORLDWIDE DIVERSIFIED HOLDINGS UPDATES SHAREHOLDERS
NEW YORK NEW YORK, August 31, 2018 – Worldwide Diversified Holdings, Inc. (OTC
PINK: WNTR) updates shareholders on its current progress.
Worldwide Diversified Holdings continues to evaluate investment opportunities in information
technology businesses, the health and wellness industry, as well as logistics and supply chain
management companies, both domestically and internationally. The company expects to complete
one or more transactions in the fourth quarter.

The logistics opportunities being evaluated include providing last mile warehousing and
distribution for corporate clients. The company is also evaluating the possibility of becoming an
Amazon Delivery Service Partner.
The company is currently working on an opportunity to further expand its investment in American
Health Network through the addition of health and wellness partners.
In addition, the company continues to look for more partners for its I-Texts platform and other
potential information technology companies.
Frank Kristan, President of Worldwide Diversified Holdings, Inc., stated: "We are working on
further development of our current portfolio to increase our revenues and provide dividends. We
are also evaluating opportunities to partner on additional transactions in 2018."
The company has announced a Tender Offer to acquire up to 2,000,000,000 of its company
common shares at price of $0.0001 to $0.01 per share. The company has extended the offer until
December 31, 2018. The company is evaluating other ways to increase shareholder value. The
company has received, as of June 30, 2018, a total of 28,033,400 common shares at prices ween
$0.0001 and $0.01. It has also received a total redemption of 650,000,000 previously issued
common shares, to reduce the amount of shares outstanding. The shares have not been adjusted to
the issued shares until the tender offer is completed.
This release is for informational purposes only and is not an offer to buy or the solicitation of an
offer to sell any shares of the Company’s common stock. The solicitation and offer to buy the
Company’s common stock will only be made pursuant to the offer to purchase and related materials
that the Company will provide to its shareholders. Shareholders should read those materials
carefully because they will contain important information, including the various terms and
conditions of the Tender Offer.

https://backend.otcmarkets.com/otcapi/company/dns/news/document/32613/content

Wow, who trades 1 share?

Time Price Volume Market
10:22:12 0.0001 1 OTO

https://quotes.freerealtime.com/quotes/wntr/TimeAndSales

'Value_Investor', earnings conference call tomorrow @ 8:00 am should be very interesting.

'concordia', Cool, go Mr. Waggoner.

Go PMCB!

'concordia', Great, I would rather invest in a company with zero debt when a life changing product is in the works, but thanks for sharing, we all are aware of this dilution.

Go PMCB!

'thenewmixer', thanks for posting this, but all biotech companies issues this statement. I'm still long after reading this and will be for a long time.

Have a great weekend to you and everyone on this board.

Go PMCB!

'stocktank2020', it will move higher when the company issues material news. Until then it will continue trade in this range.

'$Pistol Pete$', agree, patience required here. Good things will come in due time.

'$Pistol Pete$', thanks for posting the response that BioInvestor4 received from PMCB. Much appreciated, as things were starting to get out of control here.

'stocktank2020', Agree, I bought @ $0.0001 when those large trades went through. I had a GTC order in and I snatched up some more shares. I always have a GTC order in for days like today. I was pleased it executed.

'smartstocklover76', someone unloaded 147,000,000 shares @ $0.0001 and someone purchased them.

Time Price Volume Market
13:31:32 0.0001 58000000 OTO
13:31:04 0.0001 89000000 OTO
10:14:45 0.0001 575000 OTO
10:05:39 0.0002 100000 OTO

https://quotes.freerealtime.com/quotes/wntr/TimeAndSales

'A2Z', I'm thinking this time it would be different, due to the IND being filed any day now.

'A2Z'. the pps would react very well. moho though.

'BioInvestor4', hmmm, merger or partnership coming??? A person never knows what is occurring behind the scenes. It's been awful quiet lately.

'Brian903', it will happen when you least expect it. It's so quiet these days, everyone patiently waiting.

'longboarder7892, it's possible that this could occur.

'1234jklm', yes, agree!

'1234jklm', everyone is patiently waiting for the IND to be filed. I'm loving the quietness from the company. It's telling me they are working diligently behind the scenes to get this right the first time around.

I really pleased that the company is only issuing press releases when there is material news.

Go PMCB!

'The Promised Land', You're most welcome! Have a great blessed Sunday to you and all the PMCB longs here.

'The Promised Land' Agree, CIAB Bearing Great New News On The Way.

Blessed weekend to yo as well.

LJ

'fraum', Reason why there is zero volume right now is because everyone is fully loaded up here. Patiently waiting now for the IND to get submitted, including myself.

'thenewmixer', great for you. Have a wonderful weekend.

'1234jklm', sensible post, agree.

'thenewmixer', if you say so.

'thenewmixer', As a long-term investor here, the company may take as long as necessary to file the IND, as long as they get it right the first time.

I would rather wait as long as it takes to get the IND filing perfect, than rushing it through and failing.

Go PMCB, please take your time getting the IND filing perfect, thank-you.

Good morning to you 'MIKEY501'.

'$Pistol Pete$', I bet that's what he meant to say.

'Frogdollar', if this occurs, I will be a buyer. I purchased an additional 50,000 shares on the dip today.

'PINKribbon', you're welcome!

'PINKribbon' - 25 June 2018 | News

Not that old, just two days ago

Cell-in-a-Box encapsulated cells to produce interleukin-2
25 June 2018 | News

Saw this on Austrianova's Facebook this am.

IL-2 is currently approved for use at high doses to treat metastatic melanoma and renal cell carcinoma as well as at lower doses for graft versus host disease and hepatitis C virus HCV induced vasculitis.

Singapore- When it was first discovered in 1976, the cytokine interleukin-2 (IL-2) was characterized as a soluble factor with the unique ability to promote clonal expansion of immune (T and NK) cells in vitro. IL-2 is currently approved for use at high doses to treat metastatic melanoma and renal cell carcinoma as well as at lower doses for graft versus host disease and hepatitis C virus HCV induced vasculitis. Low dose IL-2 treatment has also shown promise in ischaemic heart disease and autoimmune diseases such as systemic lupus erythematosus and type 1 diabetes as well as in Wiskott-Aldrich Syndrome (Wrangle et al., 2018). The most critical issue in the use of IL-2 as a therapeutic agent is finding the suitable and appropriate window for dosing – particularly since too high doses of IL-2 usually are associated with relatively severe side effects. These dosing effects may be controllable if long term steady state levels of IL-2 production can be achieved.

Austrianova has just published a peer-reviewed paper in the respected journal International Journal of Pharmaceutics that demonstrates that IL-2 producing cells can be encapsulated in the company’s proprietary Cell-in-a-Box cellulose based cell encapsulation technology and that these encapsulated cells can then release IL-2. The data also shows regulation of IL-2 production from encapsulated cells as well as suggesting that Cell-in-a-Box encapsulated cells can be used to potentially produce other cytokines. Moreover, in the case of cancer treatment, encapsulated cells could be used to deliver multiple recombinant molecules to improve the efficacy of the anti-tumor response in a tailor made fashion to gain the maximum benefit for each individual patient while reducing side effects (Salmons and Gunzburg, 2018).

IL-2 and other cytokines are relatively small proteins with sizes in the range 5-20kDa. Austrianova’s new publication thus also looked at the size and speed of release of proteins of different sizes from standard cellulose sulphate capsules (Cell-in-a-Box) and revealed that proteins with molecular weights of up to around 70kD can be released. Further, additional data reported in the publication suggest that the conformation of the proteins as well as the charge and concentration of the protein being released may also play a role in the kinetics of release from Cell-in-a-Box encapsulated cells (Salmons and Gunzburg, 2018), a finding that has been underscored by previous studies which have shown that antibodies can be released from Cell-in-a-Box encapsulated cells (Dangerfield et al., 2013).

The ability to produce cytokines at a sustained and predefined level from encapsulated cells genetically engineered to overexpress such cytokines and implanted into patients may aid immunotherapies of cancer as well as infectious and other diseases. Given the excellent documented clinical safety record of cellulose sulphate in patients (Lohr et al., 2014), these data suggest that clinical usage of the technology may also be warranted for cancer treatment and other diseases.

https://www.biospectrumasia.com/news/26/11148/cell-in-a-box-encapsulated-cells-to-produce-interleukin-2-.html

'$Pistol Pete$', thanks for posting the link, much appreciated here. FYI, I added another 50,0000 shares to my existing position today on the dip. If the share price drops more, I will be purchasing additional shares.

'purplehp'. I added 50,000 shares to my existing position today. IND coming any day now.

'ALA16', thanks for posting the video link here on IH. I had seen this on Facebook this evening and was going to post it here on IH, but you beat me to the punch.

It's an exciting video indeed.

Yep, you got it.

Have a good night.